Abivax stock plummeted Tuesday after several patients developed cancer following a study of its ulcerative colitis treatment.

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but ...

Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...

Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a ...

Analysts have described the experimental drug as a potential best-in-class treatment for ulcerative colitis. Abivax is also ...

A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as ...

Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...

You've just been diagnosed with ulcerative colitis. Now your doctor will most likely suggest that you take certain drugs to relieve the symptoms. Here is what to expect. First, as the doctor already ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...